STOPCAP M1 Programme
Prostate cancer: STOPCAP M1 Programme. Speeding up the evaluation of therapies for metastatic, hormone-sensitive prostate cancer
Speeding up the evaluation of therapies for metastatic, hormone-sensitive prostate cancer
What is this study about?
STOPCAP M1 is a worldwide collaborative effort that aims to quickly identify which treatments work best for men with metastatic, hormone sensitive prostate cancer. This will be done through
1) Systematic reviews of treatment effects; 2) Identification of surrogate outcomes, by trying to find early measurements of prostate cancer control that predict later survival and 3) establishing a repository of patient data which will be used to tackle new questions about advanced prostate cancer and its treatment as they arise.
More information can be found here http://www.stopcapm1.org/
Who is funding the study?
It is funded by Prostate Cancer UK and the Medical Research Council
When is it taking place?
The programme of research is ongoing
Where is it taking place?
This is being led by the MRC Clinical Trials Unit at University College London brings together the results of trials carried out worldwide
Who is included?
Trials that randomised men with metastatic hormone-sensitive prostate cancer